Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

South Africa delays COVID vaccine deliveries as inoculations slow

11/24/2021 | 08:13am EST

JOHANNESBURG, Nov 24 (Reuters) - South Africa has asked Johnson & Johnson and Pfizer to delay delivery of COVID-19 vaccines because it now has too much stock, health ministry officials said, as vaccine hesitancy slows an inoculation campaign.

About 35% of adult South Africans are fully vaccinated, higher than in most other African nations, but half the government's year-end target. It has averaged 106,000 doses a day in the past 15 days in a nation of 60 million people.

Earlier this year the program was slowed by insufficient doses. Now deliveries have been delayed due to oversupply.

Across Africa, vaccination rates are lower than much of the rest of the world, with many countries struggling to secure enough doses. But some countries are now seeing rising supplies while vaccine campaigns are not gathering pace, such as Kenya.

Nicholas Crisp, deputy director-general of the Health Department, told Reuters that South Africa had 16.8 million doses in stock and said deliveries had been deferred.

"We have 158 days' stock in the country at current use," a spokesman for the Health Ministry said. "We have deferred some deliveries."

They did not say when deliveries would now take place.

Stavros Nicolaou, a senior executive of Aspen Pharmacare , which is packaging 25 million doses a month of J&J vaccines in South Africa, said most of the vaccines bound for South Africa would now go to the rest of the continent.

Nicolaou, who is also chairman of public health at business lobby Business for South Africa (B4SA), said deliveries would likely be deferred until the first quarter of next year.

Vaccines packaged at Aspen's plant are part of the African Union's agreement to buy 220 million doses from J&J.

The AU and J&J did not respond to emailed requests for comment.

A Pfizer spokesperson said: "We remain adaptable to individual country's vaccine requirements whilst continuing to meet our quarterly commitments as per the South Africa supply agreement."

South Africa's government has been seeking to boost the rate of daily administered doses.

"There is a fair amount of apathy and hesitancy," said Shabir Madhi, who led the clinical study for the AstraZeneca COVID-19 vaccine in South Africa.

To ramp up vaccinations, the government has launched pop-up vaccination centers and sought help from community leaders. It has also opened inoculations to children aged 12 to 17.

In Kenya, the Health Ministry said on Sunday vaccinations were moving too slowly among some parts of the population. Its statement did not mention any plan to delay any deliveries.

"We are ... concerned that only 18% of the elderly population is fully vaccinated and that vaccine uptake has generally slowed down in several counties following the lifting of the curfew last month," Health Minister Mutahi Kagwe said.

(Reporting by Promit Mukherjee; Additional reporting by Maggie Fick; Editing by Josephine Mason and Edmund Blair)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASPEN PHARMACARE HOLDINGS LIMITED -6.06% 203 End-of-day quote.-9.55%
ASTRAZENECA PLC 1.72% 8459 Delayed Quote.-4.17%
All news about ASTRAZENECA PLC
02:02pValneva Starts Extended Trial to Study Booster Shot of COVID-19 Vaccine; Shares Up 9%
04:32aOrange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
04:31aGermany to receive 3.8 mln doses of Novavax's new COVID vaccine in Q1
03:44aOrange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
02:01aEgetis appoints Karl Hård as Head of Investor Relations and Communication
01/24PCI Biotech Loses 10% As It Discontinues Cancer Trial To Focus On Immunotherapies
01/24AstraZeneca's Rare Progressive Disease Drug Granted US FDA Orphan Drug Tag
01/24Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots - study
01/24Chile to purchase 2 million Moderna COVID-19 vaccine doses
01/24AstraZeneca Gets European Medicines Agency's Approval to Ramp Up COVID-19 Vaccine Manuf..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 220 M - -
Net income 2021 2 516 M - -
Net Debt 2021 24 757 M - -
P/E ratio 2021 56,3x
Yield 2021 2,50%
Capitalization 177 B 177 B -
EV / Sales 2021 5,56x
EV / Sales 2022 4,56x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 112,17 $
Average target price 138,82 $
Spread / Average Target 23,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-4.17%173 383
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643